Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)

Duvelisib, an oral dual inhibitor of PI3K-δ and PI3K-γ, is in phase III trials for the treatment of chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin’s lymphoma (iNHL). In CLL, duvelisib monotherapy is associated with high iwCLL and nodal response rates, but complete remissions are rare. T...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Leukemia
Autors principals: Patel, Viralkumar M., Balakrishnan, Kumudha, Douglas, Mark, Tibbitts, Thomas, Xu, Ethan Y., Kutok, Jeffery L., Ayers, Mary, Sarkar, Aloke, Guerrieri, Renato, Wierda, William G., O’Brien, Susan, Jain, Nitin, Stern, Howard M., Gandhi, Varsha
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5540815/
https://ncbi.nlm.nih.gov/pubmed/28017967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2016.382
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars